Welcome to our next lesson. In our previous session, we established the critical difference between intention-to-treat (ITT) and per-protocol (PP) analysis, concluding that ITT is the gold standard for assessing a treatment's real-world effectiveness. Now, we will put that foundational knowledge to use.
Today, we shift from the 'how' of analysis to the 'what' of the results. Our goal is to interpret the primary efficacy and safety results from a published Phase III trial. This is where theory meets practice. You will learn a systematic way to dissect a clinical trial paper, understand its key findings, and critically evaluate its claims. By the end of this lesson, you'll be able to look at the main tables and figures in a trial report and confidently answer two fundamental questions: "Does this treatment work?" and "Is it safe?".
A Framework for Reading a Clinical Trial
Reading a dense academic paper can be intimidating. A structured approach makes it manageable. Most trial reports can be broken down into four key questions.
How To Read Clinical Trial Results and Data | Easy Research Reading Technique
This video from Finding Pharma introduces a simple yet powerful framework for reading a clinical trial paper.
Watch the initial segment from the four key questions. This will provide the mental model we'll use for the rest of this lesson.
The four questions—Why? How? What did they find? What does it mean?—provide a roadmap for our interpretation. Let's focus on the last two, which are the core of today's lesson. To understand "what they found," we first need to be clear about the statistical tools used to present the findings.
The Key Ingredients of Trial Results
When you look at the results section of a trial, you'll typically find three components for each outcome:
- A measure of effect: A single number summarizing the difference between the treatment and control groups (e.g., a Risk Ratio or Hazard Ratio).
- A confidence interval (CI): A range of plausible values for the true effect.
- A p-value: A measure of statistical significance.
Let's briefly review CIs and p-values, which are fundamental to interpretation.
What are confidence intervals and p-values?
This guide provides excellent, non-technical definitions of these core statistical concepts.
First, read the introductory bullet points at the beginning to get a high-level overview. Next, read Box 1. Hypothesis testing and the generation of p-values (this section) to understand what a p-value represents. Finally, read the section on using CIs to determine statistical significance. Notice how the CI gives you more information than a p-value alone.
The key takeaway is that while a p-value gives you a simple "yes/no" answer about statistical significance (typically at the p<0.05 threshold), the confidence interval is more informative. It tells you the magnitude of the effect and the precision of the estimate. A narrow CI means we're more certain about the effect size; a wide CI suggests more uncertainty, often due to a smaller study.
Interpreting Efficacy: Does the Treatment Work?
Efficacy endpoints measure the desired outcome of the treatment. In many trials, especially those tracking events over time (like survival after cancer treatment or time to pain relief), the primary measure of effect is the Hazard Ratio (HR).
Given your interest in data science, you can think of the "hazard" as an instantaneous rate of an event occurring at a specific point in time, analogous to a failure rate in reliability engineering. The Hazard Ratio compares this rate between the treatment and control groups.
Hazard Ratio: Interpretation & Definition - Statistics By Jim
This article from Statistics by Jim offers a very intuitive explanation of the Hazard Ratio.
Start by reading the section "What are Hazard Ratios?" to understand what an HR is and how it differs from the Risk Ratios we've seen before. Next, read the section on interpretation, which explains the meaning of HR=1, HR>1, and HR<1. Finally, read the section with the example interpretation. Pay close attention to how the meaning of the HR depends on whether the "event" is desirable (e.g., symptom recovery) or undesirable (e.g., death).
As the article explains:
- HR = 1: The event rate is the same in both groups. There is no treatment effect.
- HR < 1: The event rate is lower in the treatment group. This is good for undesirable events like death or disease progression.
- HR > 1: The event rate is higher in the treatment group. This is good for desirable events like recovery or pain resolution.
A Kaplan-Meier curve is the standard way to visualize this. The curve shows the percentage of participants who have not yet had the event over time. A faster drop indicates a higher hazard rate.
Putting It Together: A Case Study
Let's apply these concepts to a real results table from a major Phase III trial. The example below tested the drug Ramipril against a placebo in high-risk patients to see if it could prevent cardiovascular events.
What are confidence intervals and p-values?
We'll return to the same PDF, this time to analyze the example presented in Box 2.
Please read Box 2. An example of the use of confidence intervals (this section).
Let's break down the primary outcome from that table:
- Outcome: Cardiovascular event (including death)
- Effect Measure: Relative Risk (RR) of 0.78. (Note: For this trial, they used RR, but the interpretation principle is the same as for an HR). An RR of 0.78 means the risk of an event in the Ramipril group was 22% lower than in the placebo group (1 - 0.78 = 0.22).
- Confidence Interval (CI): 95% CI (0.70 – 0.86).
- Interpretation:
- Statistical Significance: The CI does not include the value of "no effect" (which is 1.0 for a ratio). Therefore, the result is statistically significant (p < 0.05).
- Magnitude and Precision: The CI tells us the true risk reduction is plausibly between 14% (from RR=0.86) and 30% (from RR=0.70). This gives us a sense of the range of the true benefit.
Notice the middle row for "Death from non-cardiovascular cause." Here, the RR is 1.03, and the CI is (0.85 – 1.26). Since this CI does include 1.0, the result is not statistically significant. We cannot conclude that Ramipril increases or decreases the risk of non-cardiovascular death.
Finally, remember the crucial distinction between statistical significance and clinical importance. A trial might find a tiny, but statistically significant, effect that isn't large enough to be meaningful for patients or clinical practice. The size of the effect (e.g., the 22% risk reduction) and the CI are what help us judge clinical importance.
Interpreting Safety: Is the Treatment Safe?
A treatment can be effective, but if its side effects are too severe, it won't be useful. Safety analysis is just as important as efficacy analysis. Safety results are typically presented in a table listing "Adverse Events" (AEs).
The interpretation is straightforward: you compare the percentage of patients experiencing each AE in the treatment group versus the control group.
When reading a safety table, look for:
- AEs that are much more common in the treatment group than the placebo group.
- AEs that are particularly severe, even if they are rare.
- Whether the pattern of AEs could explain the efficacy result. For example, in a weight-loss drug trial, if nausea and vomiting are common side effects, the weight loss might be due to the side effects rather than the drug's intended mechanism.
Conclusion
Interpreting the results of a Phase III trial is a multi-step process that requires looking beyond a single p-value. It involves a systematic evaluation of both the benefits and the harms of an intervention.
Here are your key takeaways from this lesson:
- Use a framework: Approach any trial by asking: Why was it done? How was it done? What was found? What does it mean?
- Deconstruct the results: For each endpoint, identify the effect measure (like RR or HR), the confidence interval, and the p-value.
- Interpret the Hazard Ratio (HR): HR < 1 means a lower event rate in the treatment group (good for bad events); HR > 1 means a higher event rate (good for good events).
- Use the Confidence Interval (CI): The CI is your most powerful tool. It indicates statistical significance (does it cross 1.0?) and provides a plausible range for the true effect size.
- Analyze safety data: Compare the frequency and severity of adverse events between the treatment and control groups to assess the treatment's risks.
- Synthesize: Weigh the demonstrated efficacy against the safety profile to form an overall judgment about the treatment's value.
In our next lesson, we will delve deeper into the critical appraisal of clinical trials by learning to evaluate their internal and external validity. This will equip you to assess not just what a study found, but how much you can trust its findings and to whom they apply.